Other targets that entered clinical trials of gastric cancer primarily included HER2 (NCT04660929), CEA (NCT05396300), MUC1 (NCT05239143), EpCAM (NCT05028933, NCT03563326), MSLN (NCT03941626), EGFR (NCT03740256), B7H3 (NCT04864821) and NKG2DL (NCT04550663), with no conclusions reported yet. This evidence concerns the gene EPCAM and gastric cancer.